Cargando…
Excellent Response with Ado-Trastuzumab Emtansine in a Patient with Relapsed Metastatic Breast Cancer Presenting with Pulmonary Lymphangitic Carcinomatosis
In breast cancer, aggressive tumor biology and the corresponding poor prognosis is associated with amplification or overexpression of the human epidermal growth factor receptor 2 (HER2). Trastuzumab has significantly changed the natural history of HER2-positive breast cancer. However, resistance to...
Autores principales: | Yu, Zhou, Sankar, Shobana, Huben, Marianne |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5598866/ https://www.ncbi.nlm.nih.gov/pubmed/28944112 http://dx.doi.org/10.7759/cureus.1473 |
Ejemplares similares
-
Relapsed breast adenorcarcinoma presenting as pulmonary lymphangitic carcinomatosis
por: Loh, KP, et al.
Publicado: (2012) -
Ado-Trastuzumab Emtansine in Metastatic HER2-Positive Breast Cancer
por: Callahan, Rena
Publicado: (2014) -
Case Report: Collapsing Focal Segmental Glomerulosclerosis After Initiation of Ado-Trastuzumab Emtansine Therapy
por: Hakroush, Samy, et al.
Publicado: (2021) -
Long-time Response with Ado-trastuzumab Emtansine in a Recurrent Metastatic Breast Cancer
por: Manthri, Sukesh, et al.
Publicado: (2019) -
Lymphangitic Retroperitoneal Carcinomatosis Occurring From Metastatic Sarcomatoid Chromophobe Renal Cell Carcinoma
por: Alimchandani, Meghna, et al.
Publicado: (2014)